This guidance clarifies the requirements for product name placement, size, prominence, and frequency in promotional labeling and advertisements for prescription drugs. The disclosure of the product name in promotional labeling and advertisements is important for proper identification and to ensure safe and effective use. This guidance also articulates the circumstances under which FDA intends to refrain from taking enforcement action regarding these requirements. We believe that following this guidance will allow for appropriate advertising and promotion without presenting any public health risk to patients.
News & Trends
Procurar
Recentes
- Digital label for authorised representative and importer
- MANUAL PARA REGULARIZAÇÃO DE EQUIPAMENTO MÉDICO E SOFTWARE COMO DISPOSITIVO MÉDICO NA ANVISA
- How to Prepare a PreRequest for Designation (Pre-RFD) . FDA Guidance for Industry
- Formação exclusiva Formiventos CTD MODULO 3: “Evento de alta qualidade que permitiu grande interação entre todos os participantes. “
- PREÇOS 2025: “Muito interessante e enriquecedora”
- GUIDANCE DOCUMENT Alternative Tools: Assessing Drug Manufacturing Facilities Identified in Pending Applications
- FDA Releases Draft Guidance on Quality Management System (QMS) Requirements for Premarket Submissions (October 2025
- FARMACOVIGILÂNCIA avançada: ““Excelente! Organizada e abrangente !”

